AgingResearch.NewsJoin free

Phase 3Recruiting

A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE)

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Sponsor
Kardigan, Inc. (Industry)
Enrolment
332 planned
Conditions
Symptomatic Genetic Dilated Cardiomyopathy (DCM)
Interventions
Danicamtiv
Ages
adults, older adults
Registry
NCT07771465

Full record on ClinicalTrials.gov

From the registry

Danicamtiv is an investigational medication, which means it is still being studied and has not been approved. The purpose of this study is to learn how well danicamtiv works, how safe it is, how well people can take it when used in patients with genetic or familial dilated cardiomyopathy (DCM). There are currently no approved medicines made specifically to treat genetic or familial DCM.

Primary outcomes

  • Frequency and severity of treatment-emergent adverse events (TEAEs)
  • Frequency and severity of adverse events of special interest (AESIs)
  • Frequency and severity of serious adverse events (SAEs)
  • Frequency and severity of disease-related events (DREs)

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered